July 28, 2008, Amsterdam, The Netherlands and San Antonio, TX, USA - International publisher IOS Press and the Editors-in-Chief of the Journal of Alzheimer's Disease (JAD) are pleased to announce a significant increase in the Journal's Impact Factor, from 3.058 to 4.081 for 2007 according to Thomson Reuter's Journal Citation Reports 2008. The Journal of Alzheimer's Disease continues to strengthen and build on its lead as the most prolific and highly cited journal in the Alzheimer field. With an Impact Factor of over 4, JAD is now on par with some of the most established and highly regarded journals in the neurosciences, pathology and biochemistry.
Editors-in-Chief George Perry and Mark A. Smith commented, "It is extremely rewarding to see JAD achieve the vision we set forth over a decade ago and know that the new decade will be marked by even greater service to the understanding of Alzheimer's disease. The dedication of the entire editorial board, contributing authors and our publisher, IOS Press, has certainly contributed to the success of the journal."
"The Journal of Alzheimer's Disease is one of our flagship publications," stated Einar Fredriksson, Director of IOS Press. "As publisher, one of our primary goals is to provide an open forum for original research that will expedite the fundamental understanding of Alzheimer's disease. It is extremely gratifying to see the impact that this journal is having in the field. As a specialist journal, it is particularly significant that it is ranked among the top 25% of journals included in JCR's Neurosciences category, 45th out of 211. This is considerably higher than the only other journal devoted solely to Alzheimer's research that is indexed."
The Journal of Alzheimer's Disease continues to grow and flourish. Recent expansion has included an increase to 12 issues in 2008 and the inclusion of a Review Article section under the editorial guidance of Ralph N. Martins of the Edith Cowan University, Perth, Australia.
The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes.